Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Français
March 3, 2026
Effect of Mycophenolate Mofetil Levels on Transplant Outcomes in Patients Treated with Post-Transplant Cyclophosphamide Based GVHD Prophylaxis
AL
Andrew Lin
SB
Samantha Brown
SS
Sarah Samorodnitsky
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
See all
Key Points
Higher mycophenolate mofetil levels correlate with improved transplant outcomes, especially in GVHD prophylaxis.
Notably, patients receiving post-transplant cyclophosphamide and high mycophenolate mofetil showed 20% fewer complications.
Observational analysis focused on transplant patients treated with specific immunosuppressive regimens in clinical settings.
Further studies are needed to explore optimal mycophenolate mofetil dosing for enhanced patient outcomes.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Lin et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76091c6e9836116a2d716
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.154
Effect of Mycophenolate Mofetil Levels on Transplant Outcomes in Patients Treated with Post-Transplant Cyclophosphamide Based GVHD Prophylaxis | Synapse